• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

造血细胞移植或 CAR-T 细胞治疗后血液系统恶性肿瘤患者的疫苗接种计划建议和更新。

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.

机构信息

Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

出版信息

Transpl Infect Dis. 2023 Nov;25 Suppl 1(Suppl 1):e14109. doi: 10.1111/tid.14109. Epub 2023 Jul 29.

DOI:10.1111/tid.14109
PMID:37515788
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10909447/
Abstract

Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to vaccine-preventable infections. This review synthesizes national, international, and expert consensus vaccination schedules post-HCT and presents evidence regarding the efficacy of newer vaccine formulations for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients with hematological malignancy. Revaccination post-cellular therapies are less well defined. This review highlights important considerations around poor vaccine response, seroprevalence preservation after cellular therapies, and the optimal timing of revaccination. Future research should assess the immunogenicity and real-world effectiveness of new vaccine formulations and/or vaccine schedules in patients post-HCT and cellular therapy, including analysis of vaccine response that relates to the target of cellular therapies.

摘要

接受造血细胞移植（HCT）或细胞治疗后进行再接种是患者支持性护理的重要组成部分，它有可能降低与疫苗可预防感染相关的发病率和死亡率。本综述综合了国家、国际和专家共识的 HCT 后疫苗接种计划，并介绍了血液恶性肿瘤患者中新型肺炎球菌、重组带状疱疹疫苗和 2019 年冠状病毒病疫苗制剂的疗效证据。细胞治疗后再接种的情况则不太明确。本综述重点介绍了与细胞治疗后疫苗反应不佳、血清阳性率维持、以及再接种的最佳时机相关的重要考虑因素。未来的研究应该评估新疫苗制剂和/或疫苗接种计划在 HCT 和细胞治疗后的患者中的免疫原性和真实世界效果，包括分析与细胞治疗目标相关的疫苗反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/10909447/9ecad740d0f0/TID-25-e14109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/10909447/9ecad740d0f0/TID-25-e14109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/10909447/9ecad740d0f0/TID-25-e14109-g001.jpg

相似文献

1
Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.造血细胞移植或 CAR-T 细胞治疗后血液系统恶性肿瘤患者的疫苗接种计划建议和更新。
Transpl Infect Dis. 2023 Nov;25 Suppl 1(Suppl 1):e14109. doi: 10.1111/tid.14109. Epub 2023 Jul 29.
2
Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.造血干细胞移植受者和血液恶性肿瘤患者的疫苗接种。
Infect Dis Clin North Am. 2019 Jun;33(2):593-609. doi: 10.1016/j.idc.2019.02.007.
3
Vaccination post-allogeneic hematopoietic stem cell transplantation: what is feasible?异基因造血干细胞移植后接种疫苗：可行的有哪些？
Expert Rev Vaccines. 2018 Apr;17(4):299-309. doi: 10.1080/14760584.2018.1449649. Epub 2018 Mar 21.
4
An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT.基于免疫恢复的儿科造血干细胞移植受者再接种方案：儿科 HSCT 后的再接种结果。
Transplant Cell Ther. 2021 Apr;27(4):317-326. doi: 10.1016/j.jtct.2021.01.017. Epub 2021 Jan 28.
5
Vaccinations in children with hematologic malignancies and those receiving hematopoietic stem cell transplants or cellular therapies.儿童血液恶性肿瘤患者以及接受造血干细胞移植或细胞治疗的患者的疫苗接种。
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14100. doi: 10.1111/tid.14100. Epub 2023 Jul 12.
6
Cellular Therapy in Pediatric Hematologic Malignancies.儿科血液恶性肿瘤的细胞治疗。
Clin Lab Med. 2021 Mar;41(1):121-132. doi: 10.1016/j.cll.2020.10.008.
7
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
8
Current issues in vaccines for adult patients with hematologic malignancies.成人血液恶性肿瘤患者疫苗的当前问题。
J Natl Compr Canc Netw. 2012 Nov 1;10(11):1447-54; quiz 1454. doi: 10.6004/jnccn.2012.0147.
9
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.辅助性重组带状疱疹疫苗在成人自体造血干细胞移植受者中的应用：多功能免疫反应及对临床实践的启示。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4144-4154. doi: 10.1080/21645515.2021.1953346. Epub 2021 Aug 18.
10
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.造血细胞移植和嵌合抗原受体 T 细胞治疗后对 SARS-CoV-2 疫苗的体液反应的预测因素。
Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov.

引用本文的文献

1
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
2
CAR T cell therapy for children with rheumatic disease: the time is now.用于治疗风湿性疾病患儿的嵌合抗原受体T细胞疗法：时机已至。
Nat Rev Rheumatol. 2025 Jul 2. doi: 10.1038/s41584-025-01272-3.
3
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应。

本文引用的文献

1
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.异基因造血干细胞移植后患者体液免疫对 COVID-19 疫苗接种的反应的影响因素和特征。
Front Immunol. 2023 May 3;14:1174289. doi: 10.3389/fimmu.2023.1174289. eCollection 2023.
2
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.异基因造血细胞移植后第一年的新型冠状病毒 2 型疫苗接种：一项前瞻性、多中心、观察性研究。
EClinicalMedicine. 2023 May;59:101983. doi: 10.1016/j.eclinm.2023.101983. Epub 2023 Apr 27.
3
Blood Cancer J. 2025 Jul 2;15(1):114. doi: 10.1038/s41408-025-01321-w.
4
Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.移植物抗宿主病临床管理中的现代挑战
Adv Exp Med Biol. 2025;1475:103-128. doi: 10.1007/978-3-031-84988-6_6.
5
Prevalence of VZV Reactivation and Effectiveness of Vaccination with Recombinant Adjuvanted Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Recipients-A Single-Center Analysis.异基因造血干细胞移植受者中水痘-带状疱疹病毒再激活的患病率及重组佐剂带状疱疹疫苗接种的有效性——一项单中心分析
Infect Dis Rep. 2025 May 2;17(3):48. doi: 10.3390/idr17030048.
6
Prevention of travel-related infections in solid organ and hematopoietic cell transplant recipients.实体器官和造血细胞移植受者旅行相关感染的预防
Ther Adv Infect Dis. 2025 May 12;12:20499361251338571. doi: 10.1177/20499361251338571. eCollection 2025 Jan-Dec.
7
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
8
Vaccinations in Pediatric Hematology and Oncology: Biologic Basis, Clinical Applications, and Perspectives.儿科血液学与肿瘤学中的疫苗接种：生物学基础、临床应用及展望
Vaccines (Basel). 2025 Apr 10;13(4):397. doi: 10.3390/vaccines13040397.
9
T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy.在自体嵌合抗原受体修饰的T细胞治疗之前和之后接种流感疫苗时的T细胞免疫反应。
Transplant Cell Ther. 2025 May;31(5):327-338. doi: 10.1016/j.jtct.2025.02.019. Epub 2025 Mar 1.
10
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?靶向CD19的嵌合抗原受体T细胞疗法：我们能从血液学家身上学到什么？
Lupus Sci Med. 2025 Jan 19;12(1):e001157. doi: 10.1136/lupus-2024-001157.
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
在血液恶性肿瘤影响 B 细胞的患者中，针对 COVID-19 疫苗的常见 TCRαβ 基序具有强大的 SARS-CoV-2 T 细胞反应。
Cell Rep Med. 2023 Apr 18;4(4):101017. doi: 10.1016/j.xcrm.2023.101017. Epub 2023 Mar 27.
4
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.老年人呼吸道合胞病毒预融合F蛋白疫苗
N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
5
Effectiveness of Bivalent Boosters against Severe Omicron Infection.二价加强针预防奥密克戎严重感染的有效性。
N Engl J Med. 2023 Feb 23;388(8):764-766. doi: 10.1056/NEJMc2215471. Epub 2023 Jan 25.
6
Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.对奥密克戎BA.4-BA.5二价加强针的抗体反应
N Engl J Med. 2023 Feb 9;388(6):567-569. doi: 10.1056/NEJMc2213907. Epub 2023 Jan 11.
7
Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants.造血细胞移植儿科受者中的流感疫苗
N Engl J Med. 2023 Jan 26;388(4):374-376. doi: 10.1056/NEJMc2210825. Epub 2023 Jan 11.
8
A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines.新冠疫情的一个里程碑达成——疫苗保护的一个相关因素。
N Engl J Med. 2022 Dec 15;387(24):2203-2206. doi: 10.1056/NEJMp2211314. Epub 2022 Dec 10.
9
Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children's cancer and Leukaemia Group (CCLG), and British Infection Association (BIA).成人及儿童造血干细胞移植受者疫苗接种联合共识声明：由英国血液与骨髓移植及细胞治疗学会（BSBMTCT）、儿童癌症与白血病研究组（CCLG）以及英国感染协会（BIA）联合制定。
J Infect. 2023 Jan;86(1):1-8. doi: 10.1016/j.jinf.2022.11.005. Epub 2022 Nov 15.
10
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.接受第四剂抗SARS-CoV-2疫苗的血液系统恶性肿瘤患者中COVID-19临床结局改善：一项EPICOVIDEHA报告。
Hemasphere. 2022 Oct 25;6(11):e789. doi: 10.1097/HS9.0000000000000789. eCollection 2022 Nov.